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Abstract
Background: Fundamental to vaccine development, manufacturing consistency, and product stability is an understanding
of the vaccine structure-activity relationship. With the virus-like particle (VLP) approach for recombinant vaccines gaining
popularity, there is growing demand for tools that define their key characteristics. We assessed a suite of non-intrusive VLP
epitope structure and function characterization tools by application to the Hepatitis B surface antigen (rHBsAg) VLP-based
vaccine.
Methodology: The epitope-specific immune reactivity of rHBsAg epitopes to a given monoclonal antibody was monitored
by surface plasmon resonance (SPR) and quantitatively analyzed on rHBsAg VLPs in-solution or bound to adjuvant with a
competitive enzyme-linked immunosorbent assay (ELISA). The structure of recombinant rHBsAg particles was examined by
cryo transmission electron microscopy (cryoTEM) and in-solution atomic force microscopy (AFM).
Principal Findings: SPR and competitive ELISA determined relative antigenicity in solution, in real time, with rapid turn-
around, and without the need of dissolving the particulate aluminum based adjuvant. These methods demonstrated the
nature of the clinically relevant epitopes of HBsAg as being responsive to heat and/or redox treatment. In-solution AFM and
cryoTEM determined vaccine particle size distribution, shape, and morphology. Redox-treated rHBsAg enabled 3D
reconstruction from CryoTEM images – confirming the previously proposed octahedral structure and the established lipid-
to-protein ratio of HBsAg particles. Results from these non-intrusive biophysical and immunochemical analyses coalesced
into a comprehensive understanding of rHBsAg vaccine epitope structure and function that was important for assuring the
desired epitope formation, determinants for vaccine potency, and particle stability during vaccine design, development, and
manufacturing.
Significance: Together, the methods presented here comprise a novel suite of non-intrusive VLP structural and functional
characterization tools for recombinant vaccines. Key VLP structural features were defined and epitope-specific antigenicity
was quantified while preserving epitope integrity and particle morphology. These tools should facilitate the development of
other VLP-based vaccines.
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Introduction
Recombinant virus-like particles (VLPs) are attractive candi-
dates for vaccine design because, while they resemble native
virions in size and morphology, they are non-infectious due to the
absence of a viral genome. VLP surface structure can be
engineered and optimized to achieve an enhanced immune
response due to the multiplicity of repetitive surface epitopes that
mimic the authentic surface features of native virions [1]. Since its
initial introduction (Table S1), the VLP approach has been
extended to include production in a variety of cell culture systems;
recombinant technology has successfully been used to produce
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e33235VLPs as vaccines [2,3] and as epitope presentation vehicles for
HIV (gp41) [4] and malaria [5].
Non-infectious VLPs derived from Hepatitis B virus (HBV) and
composed of the small HBV derived surface antigen (HBsAg) were
described over 40 years ago [6,7]. HBsAg VLPs are 22 nm
spherical lipid-protein particles [6,7] composed of three envelope
proteins [8], that produce a strong protective immune response
[9]. The envelope proteins result from variations in post
translational proteolytic processing of the HBV S gene protein
product and are termed the small (S), medium (M), and large (L)
form of HBsAg, or the S protein [10]. Non-infectious VLPs self-
assembled from these proteins and lipid were used for the
development of the first VLP-based vaccine and, a few years later,
recombinant DNA technology was employed to make the first
recombinant protein based vaccine with only the S form of HBsAg
(226 aa) [11].
HBsAg VLPs induce a protective immune response by
mimicking the surface features of native HBV virions by including
multiple and repetitive epitopes. Well-defined epitope structure
and less protein conformation flexibility are important for binding
to neutralization antibodies in vitro (antigenicity) and in eliciting
neutralizing antibodies in vivo (immunogenicity) for the vaccine
particles [12,13]. The immunogenic epitope of HBV recognized
by neutralizing antibody RF1 is composed of a stretch of 14 amino
acid residues, 8 of which are cysteines. Refinement of epitope
structure, a process known as maturation via disulfide bond
formation and exchange at these cysteine residues during
purification or storage over time [1,14,15,16,17], has been
previously linked to subviral particle antigenic and immunogenic
properties [12,14]. In order to ensure recombinant vaccine safety
and efficacy, it is vital to facilitate the development and
maintenance of these native virion-like epitopes on the VLP
surface [3,18] in a manner that enhances VLP stability during
protein expression, purification, and formulation. This requires
an in-depth understanding of VLP epitope structure and
function.
Although hundreds of millions of patients have been immunized
by the recombinant HBsAg VLP based HBV vaccines since the
initial introduction for human use in 1986, a definitive
understanding of the HBsAg VLP structure and the key antigenic
features is still lacking. Characterization efforts have been
hampered by the conformational heterogeneity inherent in a
lipid-protein particle with 75% protein and ,25% lipid, the
important role of disulfide bond formation for epitope structure
and function of this cysteine-rich VLP, and the presence of the S,
M, and L forms of the HBsAg protein in early preparations
[19,20,21]. In addition, traditional structural and antigenicity
characterization methods are prone to artifacts resulting from
sample processing steps (Table 1).
Structural methods, such as negative stain transmission electron
microscopy (TEM) or atomic force microscopy (AFM) on surface
immobilized VLPs, require sample adsorption to a surface,
washing steps, and additives that can result in particle dehydra-
tion, aggregation, and deformation. More widely accepted
antigenicity characterization methods, such as animal based
mouse potency assays, radio-labeled immuno assays (RIA), and
enzyme-linked immunosorbent assays (ELISA), suffer from an
indirect correlation between signal and antigen content due to
requirements for secondary labels, signal amplification, or
presence of multiple epitopes [12,13]. Furthermore, these methods
also require washing steps, sample adsorption to surfaces, and
adjuvant dissolution, which can lead to sample dehydration and
deformation. The potential for artifact introduction during sample
processing by these traditional structural and functional charac-
terization tools complicate data interpretation, as there is not a
true correlation between native epitope structure and measure-
ment.
Recent developments in non-intrusive biophysical and immu-
nochemical methods that allow analysis of samples in their native
state provide the potential for direct measurement and under-
standing of epitope structure and function [14,22,23,24,25,26].
Surface plasmon resonance (SPR) directly and rapidly monitors
antigenicity development during epitope refinement in real time
without the requirement of a label, where the signal is proportional
to the mass deposited onto the sensor chip surface during
biomolecular interactions [23]. An optimized solution competitive
ELISA, performed with a neutralizing monoclonal antibody (mAb)
that targets clinically relevant epitopes [23], quantitatively tracks
the development of virion-like epitopes on VLPs in solution or
when bound to particulate aluminum-based adjuvant. CryoTEM
allows determination of the native, hydrated structure of VLPs
[24,25], and in-solution AFM visualizes VLP surface features
without particle deformation or drying [14,22,26]. Here, we have
evaluated the use of these biophysical and immunochemical
methods in concert as a potential novel suite of non-intrusive VLP
characterization tools by applying them to the characterization of
the VLP-based vaccine against HBV [11].
Results
Functional Activity of rHBsAg Epitopes with SPR and
ELISA
Since mouse potency tests and in vitro relative potency analyses
reflect the overall immune response in animals or multiple
epitopes on antigen, probing the antigenicity of vaccine prepara-
tions and process intermediates, and the immune response with
respect to a given epitope or a set of epitopes helps to assess the
epitope-specific antigenicity or the functionality of the binding
antibody titers. RF1 and A1.2 are two protective murine
monoclonal antibodies (mAbs) known to recognize the immune
dominant region on the surface loop of HBsAg near the dimer
interface and have high degree of sensitivity to VLP surface and
epitope conformation [12,23,27,28,29,30]. Therefore, a panel of
mAbs, with these two mAbs included, was used to analyze the
rHBsAg particle in solution over the course of bioprocessing and
the final product bound to adjuvant by competitive ELISA and
SPR.
The solution competition sandwich ELISA experiment revealed
increased antigenicity for spontaneously matured and redox-
refolded particles (Figure 1A), and for particles further along in
bioprocessing (Figure S1A). Different mAbs displayed different
levels of sensitivity for the antigen and varying levels of end point
antigenicity, with RF1 showing among the highest antigenicity
(Figure S1B). RF1 is the only mouse IgG that has been
demonstrated to have protective activity in non-human primates
against viral challenge [27,28,31]. This mAb binds the HBsAG
epitope at an intramolecularly disulfide-bonded cyclic peptide
important for viral entry [27,28,31].
The SPR setup allowed quantitative monitoring of VLP
maturation over time and supported results obtained by the
ELISA platform that antigenicity is increased for HBsAg VLPs
with higher disulfide content. Increased antigenicity was observed
over the course of maturation and for redox-treated rHBsAg
VLPS (Figure 1B). Marked increase in antigenicity was observed
for heat- and redox-treated rHBsAg VLPs (Figure 1C). The latter
were over 10-fold more antigenic than freshly purified VLPs and
had comparable antigenicity to plasma-derived particles
(Figure 1C). Together with our ELISA study, these results support
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which occurs during VLP maturation in bioprocessing, induces
changes in epitope structure that are vital for optimal antigenicity
[12,14,23,28].
Almost all HBsAg based vaccines are administered with
aluminum adjuvants, thus understanding the available epitopes
on the adjuvanted VLPs is critical as it mimics to some degree the
antigen presentation after intra muscular injection. Lot-to-lot
comparison of inhibition curves obtained for antigen in solution
with antigen bound to adjuvant showed similar IC50 values when
monitored with RF1 (Figure 1D and Table S2). This indicates that
antigenicity was not adversely affected by adsorption to adjuvant.
SPR and competitive ELISA, with conformation-sensitive and/
or disulfide-dependent mAbs allowed quantitative determination
of epitope development during process manufacturing and in final
vaccine products by monitoring relative antigenicity in solution, in
real time, and with rapid turn-around. Utilization of multiple
mAbs in conjunction with a quantitative assay that could be
performed for the antigen in solution and bound to adjuvant
assured more complete understanding of the VLP key epitope
make up and correlation to vaccine immunogenicity. These two
quantitative antigenicity analysis methods are complementary to
the commonly used sandwich ELISA and mouse potency assays
for vaccine batch release and stability testing [12,13]. Similar
application of the epitope-specific antigenicity analysis using
competitive ELISA (IC50) was recently reported for another
recombinant based VLP, human papillomavirus (HPV) type 16,
using a panel of mAbs to delineate the specific changes in mAb
binding pattern with or without VLP disassembly/reassembly
[32].
Table 1. Non-intrusive biophysical and immunochemical methods evaluated here for VLP characterization compared with
conventional techniques.
Conventional Method Non-intrusive Toolbox
Transmission Electron
Microscopy (TEM)
TEM with Negative Stain Sample Preparation Cryo-TEM with Vitrified Sample Preparation
- Adsorption to surface of grid can cause particle
deformation and aggregation
- No adsorption to surface
- Washing steps can change sample buffer conditions - No washing steps
- Heavy metal stain can cause particle deformation
and dehydration
- No heavy metal stain; Sample is preserved in formulation
buffer in frozen-hydrated state
Potential for changes in epitope structure during
sample processing
Epitope structures are preserved during sample processing
Atomic Force
Microscopy (AFM)
AFM on Mica Surface with Dried Samples AFM in Solution on Mica Surface with Flow Cell
- Adsorption to surface of mica can cause
particle deformation, aggregation, and dehydration
- No adsorption to surface
- Washing steps can change sample buffer conditions - No washing steps
- Scanning mode can cause particle deformation - Flow cell analyzes sample in solution; Tapping mode is less
likely to cause particle deformation
Potential for changes in epitope structure during
sample processing
Epitope structures are preserved during sample processing
Antibody Binding or
Antigenicity Analysis
Radio-labeled Immuno Assay (RIA) or
Enzyme-linked Immunosorbent Assay (ELISA)
Surface Plasmon Resonance (SPR)
- Sample binding is analyzed adsorbed to a surface - Sample binding is analyzed in solution
- Radio or enzyme label required for binding signal
amplification
- No label required for binding signal amplification; Signal is
directly proportion to mass deposited on surface; Assay can be
used for real-time kinetic monitoring or end-point binding
analysis [23]
- Turn-around time is 0.5-3 days - Turn-around time is 20-30 minutes
Indirect link between signal and binding Direct link between signal and binding
ELISA for Antigenicity
Determination for Vaccines
Sandwich ELISA Solution Competitive ELISA*
- Adsorption to surface can cause particle
deformation and dehydration
- No adsorption to surface
- Washing steps can change sample buffer conditions - No washing steps; Sample is analyzed in solution
- Dissolution of sample from particulate adjuvant
required for analysis
- Sample can be analyzed upon adsorption to adjuvant
Potential for changes in epitope structure
during sample processing
Epitope structures are preserved during sample processing
*The solution competitive ELISA measures the accessible epitopes on VLPs adsorbed to particulate adjuvant. This method is used to probe the stability samples upon
prolonged storage in a more faithful manner as to the intact and accessible epitopes. In addition, this method may also mimic the in vivo antigen presentation to some
degree without the needs to dissolve the aluminum adjuvant, which is co-injected with antigen during immunization.
doi:10.1371/journal.pone.0033235.t001
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The conformational heterogeneity [19,20,21] of HBsAg parti-
cles has long hampered a definitive structural understanding of the
key antigenic features of this cysteine- and proline-rich VLP (Table
S3). Here we analyzed the size, shape, and morphology of a
conformationally homogenous, redox-treated form of yeast
derived HBsAg vaccine particles [23] (rHBsAg) using cryoTEM
and in-solution AFM. These particles were assembled from only
the active S-protein component of the HBV vaccine. Visual
inspection of AFM and cryoTEM images revealed mostly
spherical rHbsAg VLPs with slightly amorphous boundaries
(Figure 2A–B). Higher magnification AFM views of the particles
showed slight protrusions from the VLP surface in a regular
pattern (Figure 2C) that was in agreement with the pattern of
protrusions observed in 2D class averages obtained from
cryoTEM data (Figure 2D). Size analysis of spherical VLPs by
in-solution AFM measurements revealed an average particle size
of ,22 nm in agreement with previous studies [26,27] (Figure
S2B). Quantitative particle size distribution analysis of 266
particles in cryoTEM images revealed a maximum particle Feret
diameter ranging 18.5–22.7 nm and a circularity measure of
0.89+/20.03, indicating that the VLP morphology deviates from
perfect circularity (Figure S2A).
VLP morphology was further investigated before and after
oxidative treatment. In-solution AFM revealed that, after oxidative
treatment, mature rHBsAg VLPs have better-defined surface
protrusions and a lesser degree of particle flattening (Figures S3).
Similarly, cryoTEM images showed more compact VLP particles
with better-defined borders in non-reducing environments (Figure
S4). These results combined with our SPR and ELISA results
support previous studies [12,14,23], and suggest a fundamental
link between antigenicity, disulfide bond formation, and epitope
structure.
VLP Structural Characterization by CryoTEM 3D
Reconstruction
Only spherical, single rHBsAg VLPs were selected from 211
cryoTEM images and subjected to 2D alignment and classification
in preparation for 3D reconstruction. The resulting class averages
revealed two predominant particle populations, measuring
,20 nm and ,22 nm in diameter, respectively (Figure S5). Each
Figure 1. Measurement of rHBsAg VLP antigenicity by SPR or solution competitive ELISA. (A) Solution competition ELISA measurement
(or relative IC50s) for freshly prepared (n=5), heat-treated (n=5), and redox-refolded (n=3) rHBsAg VLPs; (B) A1.2 epitope maturation over time in
PBS and with a redox buffer-reduced (GSH) and/or oxidized (GSSG) forms of glutathione; (C) relative antigenicity by SPR with A1.2 and RF1 (n=12);
(D) Relative antigenicity of rHBsAg in aqueous solution as well as when adsorbed onto particulate adjuvant.
doi:10.1371/journal.pone.0033235.g001
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and refined to a similar 3D structure (Figure S6); as such, particle
size populations were combined and subjected to 3D refinement
with octahedral symmetry [19,33]. The resulting map presented
with roughly spherical morphology and ‘‘knuckle’’-like protrusions
projecting from a smooth surface (Figure 3A).
The basic structural morphology was in agreement with that
obtained for human plasma-derived particles [12,23], which are
comparable to the redox-refolded rHBsAg VLPs used in our study.
It is possible that the variety of proposed structures (Table S3) may
be the result of heterogeneity, not only in the S, M, and L forms of
HBsAg for plasma-derived particles or tubules, but also in degree
of cross-linking and proper disulfide bond pairings, which are vital
for retention of an ordered structure with key antigenic features
[14,34]. Segmentation of the cryoTEM map into discrete regions
of density resulted in 24 ‘‘knuckle’’-like protrusions, presumed to
be S-protein, separated by regions of lesser density, presumed to
be lipid (Figure 3B). In accordance with octahedral symmetry, the
rHBsAg particle showed rotational axes of 4-, 3-, and 2-fold
symmetry, obtained by rotating the particle by 45u (Figure 3B). A
cross section of the map revealed an empty internal core
surrounded by a tightly packed S-protein frame with lipids
interspersed (Figure S7).
Extracting a single protrusion with associated lipid indicated
how the trans-membrane S-protein-containing protrusions were
positioned within the VLP lipid layer (Figure 4). The lipid layer
itself was composed of two discrete regions, an outer section, likely
composed of phospholipids [20], that was fairly uniform and
ordered and whose ,2.5 nm width corresponded to that of a lipid
monolayer (Figure 4B, ‘‘oL’’ and Figure S8C), and an inner
section, likely composed of non-polar triglycerides [20], that was
more amorphous in appearance and more variable in width
(Figure 4B, ‘‘iL’’ and Figure S8C). We segmented each ‘‘knuckle’’
of protein density into three general regions called body, shoulder,
and arm (Figure 4B, ‘‘bd’’, ‘‘sh’’, ‘‘ar’’), that were differentially
positioned with respect to the ordered, outer lipid monolayer and
the disordered, inner nonpolar lipid layer. The arm and shoulder
regions of each S-protein containing density wrapped around the
body region of a neighboring protein density to provide a solid
framework of repeating S-protein densities around which lipids
were organized [20,21,31,35] (Figure 5A). Notably, the body of
the repeating S-protein framework organized the outer lipid
monolayer, in contrast to the inner lipid monolayer which was less
organized and immersed the arm regions of the protein densities
(Figure 5B).
Quantitation of 3D Structural Results
In order to further define the structural properties of rHBsAg
VLPs, we performed quantitative measurements of the cryoTEM
map (Table 2 and Figure S8). Measurement of the size of the 3D
map revealed diameters ranging 19.4–21.7 nm, with the twofold
rotational axis view having an average diameter of ,22 nm, the
threefold rotational axis having an average diameter of ,21 nm,
and the fourfold rotational axis view having an average diameter
of ,20 nm (Figure S8A). Whereas previous studies interpreted the
observation of multiple size populations in cryoTEM images as
being physically different particle sizes [19], our analysis suggested
that these are the same particle viewed from different rotational
axes.
The S-protein containing protrusions were spaced ,7.0 nm
apart along the threefold rotational axis, ,7.4 nm apart along the
twofold rotational axis, and ,9.2 nm apart along the fourfold
rotational axis (Figure S8B) and projected ,2.2 nm from the
smooth surface (Figure S8C). The outer lipid layer measured
Figure 2. AFM and cryoTEM analysis of rHBsAg particles. (A) AFM field of view, (B) cryoTEM field view, (C) high-magnification AFM view, and
(D) two-dimensional CryoTEM class averages of rHBsAg VLP particles. Note that image contrast is reversed in (B) and (D).
doi:10.1371/journal.pone.0033235.g002
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in width (Figure S8C). This is in agreement with a Dane particle
diameter of 42 nm and a nucleocapsid (HbcAg) radius of 13.5 nm
[20,35], which leaves 6.5 nm for the rHBsAg protein-lipid layer,
and removing 2.2 nm protrusions, leaves 4.3 nm total for the
ordered outer lipid monolayer (,2.5 nm) and the variable inner
nonpolar lipid layer (,2.2 nm).
Based on the total volume occupied by protein densities and
lipid densities, the rHbsAg particle had a protein and lipid
composition of 78% and 22%, respectively (Table S4). The
volume occupied by individual protein densities corresponded to a
MW of ,100 kDa, which can accommodate four S-protein
monomers of ,25 kDa MW each [21], to give 96 S-protein
monomers per rHBsAg VLP. This supports earlier work
showing that mAbs RF1 and A1.2 only bind higher MW
bands of S-protein in a non-denaturing Western Blot [30] and
the dimer of dimers model [21] in which each protrusion consists
of two S-protein dimers for a total of 48 dimers per rHBsAg
VLP. Other results show that better-maintained protrusion
heights and increased antigenicity are observed by in-solution
AFM, SPR, and ELISA after rHBsAg VLP maturation or
redox treatment [12,14,22] (Figures 1, S1, S4, S5). Moreover,
the most common escape mutant of HBsAg in HBV alters the
epitopes of the ‘‘a’’ determinant—an immunodominant region
Figure 3. CryoTEM map of rHBsAg lipid-protein particle. (A) The resulting 3D map presented with roughly spherical morphology with
‘‘knuckle’’-like protrusions projecting from a smooth surface. (B) Segmentation of the map revealed regions of high density, presumed to be protein,
surrounded by regions of lesser density, presumed to be lipid. Map shown end-on for the 4-fold (top left), 2-fold (top right), and 3-fold (bottom left)
views.
doi:10.1371/journal.pone.0033235.g003
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[30,31]. Together, our results and these studies suggested that
these ‘‘knuckle’’-like protrusions house clinically relevant epitopes
of HBsAg VLPs.
The body of each protrusion was partially submerged in the
lipid monolayer, with ,18 kDa of tetrameric S-protein protruding
into the extracellular space (Table S4), able to accommodate a
stretch of amino acid residues (AA 105–156) in the antigenic loop
most implicated in infectivity and antigenicity [27,28]. The arm
and shoulder wrapped around the body of a neighboring protein
density and were partially submerged in the lipid monolayer, with
,31 kDa total of tetrameric S-protein from both arm and
shoulder regions protruding into the nonpolar lipid layer on the
inside of the VLP. Together, the regions of the body, arm, and
shoulder that reside in the ordered lipid monolayer accounted for
,51 kDa of tetrameric S-protein density. These numbers were in
agreement with those determined by existing structural studies
and previous estimates based on primary sequence analysis
[21,31], though more of the S-protein tetramer (,50%) appeared
to be submerged in the lipid layer in our structure than what
was previously observed. This is likely due to tighter packing
resulting from our homogenous recombinant S-protein (versus S,
M, L in other structures) and because we used a fully and
uniformly matured particle via redox treatment for structure
determination.
Discussion
Structural Model for rHBsAg VLP Antigenicity
Together with previously published results, the analysis of the
3D TEM structure presented here reveals a structural model for
the rHBsAg vaccine particle that is consistent with previous results
regarding the antigenic features, lipid-protein arrangement, and
overall particle architecture [17,19,20,21,27,28,31]. The rHBsAg
VLP architecture is driven by a framework of 24 repeating protein
units, each composed of a tetramer of S-protein monomers, for a
total of 96 S-protein molecules surrounded by a tightly packed
monolayer of mostly polar lipids. Particle stability is conferred by
trans-membrane helix-helix interactions between S-protein mono-
mers and lipid-protein associations [20,22,35]. The in-membrane
portion of S-protein is cemented in the lipid monolayer on the
inside of the VLP by nonpolar lipids. The top of each S-protein
tetramer likely comprises the ‘‘a’’ determinant and protrudes
slightly into the extracellular space, where it presents the vaccine
epitope. The main antigenic loops of a tetramer of S-protein
monomers, observed as a protrusion in the 3D structure, consists
of 32 cysteine residues that are vital for forming the virion surface
like structure of this key antigenic protrusion with 36 prolines
providing some conformational flexibility. The epitopes on these
surface protrusions, relying on the proper disulfide bond pairings
at the dimeric and tetrameric interface, are critically important for
Figure 4. Structural features of the protein containing protrusion and surrounding lipid layer. (A) A single protein protrusion with
associated lipid was segmented from the 3D map and (B) various structural features present in the lipid and protein densities were identified.
The protein unit is composed of a body (bd), shoulder (sh), and arm (ar) region, and the lipid layer is composed of an outer layer (oL) and an inner
layer (iL).
doi:10.1371/journal.pone.0033235.g004
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unit wrap tightly around the body (bd) of a neighboring unit to form a tight framework of protein around which lipids are interspersed. (B) The body
(bd) organizes the outer lipid layer (oL), whereas the inner lipid (iL) layer surrounds the arm region of the S-protein containing densities that protrude
into the inside of the VLP.
doi:10.1371/journal.pone.0033235.g005
Table 2. A Summary of the Structural Properties of the yeast-derived rHBsAg VLP determined by CryoTEM.
Property Result Literature References
rHBsAg Particle Particle Symmetry Octahedral [19], This work
Particle Symmetry Axes 4:3:2 [19], This work
Particle Diameter, 3-fold view 21 nm This work
Particle Diameter, 4-fold view 20 nm This work
Particle Diameter, 2-fold view 22 nm This work
Number of Protrusions 24 [19], This work
Protrusion Spacing, 2- and 3-fold 7 nm This work
Protrusion Spacing, 4-fold 9 nm This work
Protrusion Height 2 nm [19,21], This work
rHBsAg Protein Monomers Number of Protein Monomers per Protrusion 4 [21], This work
Number of Protein Monomers per Particle 96 [21], This work
Number of Cysteine Residues per Protrusion 32 [21], This work
Number of Cysteine Residues per Particle 768 [21], This work
rHBsAg lipid and protein Width of Outer Lipid Monolayer 2.5 nm This work
Width of Inner Lipid Layer Variable This work
MW of Protein Monomer, extracellular 4.5 kDa This work
MW of Protein Monomer, Outer Lipid monolayer 12.8 kDa This work
MW of Protein Monomer, Inner Lipid Layer 7.8 kDa This work
Lipid Composition 22% [19,21], This work
Protein Composition 78% [19,21], This work
doi:10.1371/journal.pone.0033235.t002
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is important to assure the desired epitope formation, determinants
for vaccine potency, and particle stability during bioprocess and
subsequent formulation and storage.
A Novel Toolbox for Vaccine Characterization
We have presented, using rHBsAg particle as a case study, two
non-intrusive methods, cryoTEM and AFM, for structural
characterization of recombinant VLPs. In addition, two antige-
nicity analysis methods using monoclonal antibodies, SPR and
ELISA, provide quantitative tools to track the development of
clinically relevant epitopes or to monitor changes during
bioprocessing or storage and to ensure manufacturing consistency
and product stability [12,14]. These structural and functional
methods are beneficial during early development phases of a
vaccine candidate and post licensure to support routine manufac-
turing and process improvement because in vitro antigenicity, in an
epitope-specific manner, is the best surrogate marker for in vivo
immunogenicity or vaccine efficacy.
While the combined structural and functional vaccine charac-
terization enabled by this toolbox has great utility, the methods
presented here are not without potential limitations. The structural
component of the toolbox requires sophisticated equipment and a
high degree of user expertise to collect and analyze data.
Moreover, while these tools are capable of providing quantitative
data on particle size and morphology, they are not well suited to
high-throughput applications. For high-throughput studies, typi-
cally conducted at the early stages of development, more standard
technologies such as dynamic light scattering (DLS), high
performance size exclusion chromatography (HP-SEC), and, more
recently, nanoparticle-tracking analysis (NTA), are more practical.
Nevertheless, the most complete understanding of a given vaccine
drug product will likely be achieved by combining the high-
throughput methods with the orthogonal tools presented here.
While these methods were demonstrated with recombinant
protein based VLPs, these techniques should also be useful for
characterizing other virion- or VLP-based vaccines or drugs for
gene therapy based on live or attenuated viruses. Depending on
the biologic in question, a few considerations are provided here to
aid in the application of this toolbox. Heterogeneity in virion or
VLP size, morphology, and composition could confound the ease
with which 3D information is obtained. For VLPs derived from
non-enveloped viruses (e.g. HPV, Norovirus, Rotavirus) this tends
to be less of a concern, as these particles tend to be fairly
homogenous in size, morphology, and composition. For vaccines
derived from enveloped viruses (e.g. Respiratory Synctial Virus,
Influenza, Herpes Virus, HIV, HBV), application of the toolbox
may require additional care to overcome limitations imposed by
heterogeneity in size, shape, and composition. In the case of the
current work, structural information was more readily obtained
after reducing population heterogeneity via recombinant technol-
ogy, and since this approach is increasingly the trend in vaccine
engineering, this type of application should become more
accessible in the future.
A strong understanding of the structure-activity relationship is
crucial for all the stages of vaccine design, development, and
manufacturing. In the recent case of the successful production of a
quadrivalent HPV vaccine (GardasilH licensed in 2006), ,15 years
elapsed between the initial report of VLP formation with a single
capsid protein and the appearance of the commercial product
[1,2]. We hope that the toolbox of epitope-preserving and
contemporary methods presented here (Table 1) will facilitate
the structural and functional characterization of other VLPs in the
future, thus expediting the development process for vaccines under
clinical trials and assuring manufacturing consistency for licensed
vaccines.
Materials and Methods
Recombinant HBsAg VLPs
rHBsAg was over-expressed and purified from Saccharomyces
cerevisae as previously described [36] and subjected to in-solution
AFM, SPR, and solution competition ELISA before and after
spontaneous (heat)- or redox-assisted maturation [14].
SPR (Biacore) Antigenicity Assessment
Real time antigenicity monitoring and end point antigenicity
assessment were performed as described recently [23]. Briefly,
using a Biacore 3000 instrument, CM5 sensor chips were prepared
by covalently coupling rabbit-anti-mouse IgG Fcc antibodies
(RAMFcc) through the carboxylate groups in the dextran matrix
on the sensor chip and the amine groups on the RAMFcc using a
Biacore Coupling Kit. The immobilized RAMFcc antibodies were
used to capture a Hepatitis B murine monoclonal antibody (mAb)
IgG – RF1 or A1.2. VLP samples (10 mg/mL rHBsAg) were
injected with a constant volume and constant flow rate, and extent
of binding measured as the mass increase at the sensor chip.
Results from the samples are compared to a reference lot tested in
adjacent cycles.
Fluorescence ELISA for IC50 Antigenicity Measurement
Briefly, a fixed amount of rHBsAg on plate and varying amount
of rHBsAg VLPs in solution were allowed to compete for binding
with a constant concentration of anti-HBsAg mAbs at 10 or
20 ng/mL. Serial dilutions (1.5-fold) of a reference lot and of test
samples were performed on the VLP coated assay plate using a
Beckmann BiomekH 2000 or 3000 Laboratory Automation
Workstation. Bound antibody was quantitated with an alkaline
phosphatase-conjugated rabbit anti-mouse IgG antibody and 4-
methylumbelliferyl phosphate (4-MUP) (Virolabs, Chantilly, VA)
as a substrate [37,38]. IC50 values were calculated using a four
parameter logistic fit with GraFit software or Excel, and compared
to that of a reference lot tested on the same plate.
In-solution AFM
Samples were analyzed by in-solution AFM as described
previously [14]. Briefly, aqueous sample was deposited on a
freshly cleaved mica surface (1/40 diameter) at room temperature
to allow passive adsorption, followed by a gentle rinse with de-
ionized water. AFM images were collected with Digital Nanoscope
III MultiMode AFM TappingModeTM (Digital Instrument,
Santa Barbara, CA) in fluid at ambient temperature. The
quantitative statistical assessment was performed with the image
software supplied by Digital Instrument.
CryoTEM imaging and analysis
CryoTEM sample preparation and imaging. The samples
were preserved in a thin layer of vitrified ice over continuous
Carbon layered over C-Flat holey carbon films supported on 400
mesh copper grids. Low dose cryoTEM was performed on a FEI
Tecnai Spirit EM operating at 120 keV equipped with a FEI
Eagle CCD camera. 218 images were acquired using a dose of
,25 e-/A ˚2 at 52,0006 (0.21 nm/pixel) magnification and a
defocus range of ,1–3 mm underfocus.
CryoTEM image processing and initial models. Particles
were selected using image processing interface APPION [39] by 1)
template matching [40], using filtered versions of projections of
EMDB 1158 and 1159 [19] and 2) difference of Gaussians
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particles (4.24 A/pixel) and 2) 33,962 particles (2.12 A/pixel). The
CTF of each image was estimated using ACE [42] and corrected
using EMAN [43]. For 3D reconstruction, we utilized the
following initial model approaches: a) The maps produced by
Gilbert et al. [19] (http://www.ebi.ac.uk/msd/index.html, EBI #
1158, 1159) were low-pass filtered to 10 nm, and scaled to a
sampling size of 0.212 nm/voxel; b) Initial models were generated
using common lines in EMAN [43] with C4 symmetry.
CryoTEM 3D reconstruction: refinement. We used
EMAN [43] and Spider [44] to produce a 3D map. Particles
were subjected to 8 rounds of EMAN [43] refinement using 4
rounds at 5u angular increments followed by 4 rounds at 3u
angular increments. Octahedral symmetry was imposed. After
each refinement iteration, classes were subjected to reference-free
classification using Spider [44] to eliminate subclasses that match
poorly to the initial model. The final reconstruction analyzed in
this manuscript utilized particles selected using template matching
[40], the 1159 Gilbert map [19] as an initial model, and resulted in
a 3D map with a nominal resolution of ,1.5 nm according to the
FSC0.5 resolution criterion. A total of 20,335 particles passed
selection criteria allowing them to contribute to the final 3D map.
Segmentation of 3D volume obtained by cryoTEM. The
resulting 3D map was segmented using the ‘‘Segger’’ and ‘‘Mask’’
functionalities in the visualization package chimera [45]. Protein
and lipid densities were determined via visual assessment of the
resulting ‘‘Segger’’ regions and examination of the 3D map at
varying density thresholds. In order to physically segment the
protein and lipid densities from the 3D volume, the ‘‘Mask’’
command was utilized. Segmentation of individual lipid layers and
the individual protein densities were also achieved using ‘‘Segger’’.
Volume and Molecular Weight calculations of segmented
3D map. The volume of each segmented unit was obtained
using the ‘‘Measure Volume’’ functionality in chimera [45].
Briefly, the volume measured for a single segmented region of
protein density was 141.4610
3 A ˚ 3 at a display threshold of 2.8,
giving a MW of 117.6 kDa [46], corresponding to 4 S-protein
monomers. The volume corresponding to this unit was normalized
to 100 kDa for further calculations. The volume of protein
residing in different parts of the VLP was obtained by the
‘‘Measure Volume’’ functionality after using the ‘‘Eraser’’ sphere
in chimera.
Supporting Information
Figure S1 HBsAg Antigenicity for different mAbs. (A)
Solution competition ELISA profiles for deriving IC50 vales and
the fitted lines for RF1 on HBsAg samples with different degrees of
maturation. (B) Different mAbs displayed different level of
sensitivity for HBsAg products with varying end point antigenicity.
(EPS)
Figure S2 HBsAG particle size distributions. (A) AFM
images obtained in solution and statistical analysis for size
distribution determination on two independent production
batches. (B) Quantitative particle size distribution analysis of 266
particles extracted from CryoTEM images revealed a maximum
Feret’s diameter of 20.6+/22.1 nm and a minimum Feret’s
diameter of 15.7+/21.7 nm. The circularity of particles was
determined by taking the ratio of maximum and minimum Feret’s
diameters, and measured 0.89+/20.03 for HbSAg particles; a
circularity measure of .0.92 is considered spherical.
(EPS)
Figure S3 AFM images obtained in solution for different
processes of HBsAg VLPs prior to and post KSCN
treatment. More surface features and less flattening were
observed after the oxidative KSCN treatment.
(EPS)
Figure S4 CryoTEM images of rHBsAG particles (A)
before and (B) after DTT treatment, and (C) of plasma-
derived HBsAg particles. Particle boundaries were more
defined and spikes were better preserved for rHBsAG particles
that were not treated with DTT and that are plasma-derived.
(TIF)
Figure S5 Class average analysis of rHbSAg particles
from CryoTEM data. (A) 2D alignment and classification of a
subset of particles revealed (B) two size populations of particles
with small (left two panels) and large (right two panels) diameters.
(C) Automated determination of average particle diameters from
class averages revealed a bimodial size distribution with mean
values of 20.6+/20.8 nm and 22.5+/20.6 nm.
(EPS)
Figure S6 A summary of the 3D maps generated during
model refinement with octahedral symmetry. (A)
Using Gilbert initial model (1) 1158 and particles selected by
template selection with 1158, (2) 1159 and particles selected by
template selection with 1159, (3) 1158 and particles selected
by DoG picker, and (4) 1159 and particles selected by DoG picker.
(B) Using EMAN StartAny with C4 Symmetry initial models
generated with (1) 1158 particle stack and refined with 1158
particle stack, (2) 1159 particle stack and refined with 1159
particle stack, (3) DoG particle stack and refined with 1158 particle
stack, and (4) DoG particle stack and refined with 1159 particle
stack.
(EPS)
Figure S7 The refined 3D map with octahedral symmetry with
the front half cut away to reveal an internal particle that is empty.
Corresponds to Figure 3B.
(EPS)
Figure S8 Quantitative measurements of the 3D map.
(A) Particle diameters for each of the 2-fold, 3-fold, and 4-fold
rotational axis views. The average particle diameter is 21.7 nm,
21.0 nm, and 20.3 nm respectively. (B) Measurement of the
distance between protrusions reveals spacing of ,7.4 nm along
the 2-fold axis, ,7.0 nm along the 3-fold axis, and ,9.2 nm along
the 4-fold axis. (C) Measurement of the dimensions of the lipid
layer and the distance with which the protein protrudes from the
VLP.
(EPS)
Table S1 Initial discovery of VLPs and key vaccines for human
use or in clinical trials based on VLP approach (1968 to 2011).
(DOC)
Table S2 Quantitative analysis of RF1 epitope in HBsAg VLPs
using competitive ELISA (rel IC50) for lot-to-lot consistency.
(DOC)
Table S3 Structural characterization with CryoTEM on subvi-
ral particles of HBV and the main conclusions.
(DOC)
Table S4 Quantitative analysis of Segmented CryoTEM
Volume.
(DOC)
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